Covid-19 epidemic, shown global drug discovery market is growing rapidly

▴ Covid-19 epidemic, shown global drug discovery market is growing rapidly
InSilicoTrials presents a suite of highly innovative products that could revolutionize the global pharmaceutical industry

The global drug discovery market is growing rapidly: it is expected that it will reach 71 billion dollars by 2025, while in 2016 it was worth just 35.2 billion (source Statista 2020). Today, developing a new drug takes about 10 years of experimentation and an estimated investment in R&D between 1 and 3 billion dollars. As if that wasn’t enough, very few drugs actually hit the market: the largest majority of them are abandoned after years and years of very expensive research.

The Covid-19 epidemic has shown the urgent need to speed up this process, obviously without sacrificing safety. Simulation allows to establish in the very early stages of testing a new molecule, instead of after many years of work, if the molecule possesses all the safety requirements to be able to arrive one day on the market. In silico trials are strongly supported by regulatory bodies such as FDA and EMA.

Simulation, which has already been widely used for decades in sectors such as Automotive and Aerospace to produce increasingly safe and cutting-edge cars and aircraft, is still little used in the pharmaceutical field. Why? The reasons are essentially three: the very high costs to develop new computational models; the costs for the IT infrastructure and the software needed to make them work; the high expertise required for their use: as a consequence, today only large pharmaceutical companies can afford to use simulation.

InSilicoTrials, a rapidly expanding Italian startup with offices in Milan, the Netherlands and the United States, has developed an innovative platform that significantly reduces the costs and development times of new drugs by 40/60%. The goal of InSilicoTrials is to facilitate access to these technologies even for small and medium-sized pharmaceutical companies.

InSilicoTrials provides Pharma companies with the best computational models available worldwide that its team of scientists continuously selects from the most renowned universities and which are already able to support certification by regulatory bodies. A group of engineers and developers then works on these models to simplify the interface and use, so that, once uploaded on the platform, they can also be used by researchers who do not have expertise on digital simulation. In a pay-per-use way, the pharmaceutical company pays only when it uses the model, thus considerably cutting costs and allowing its employees to access the technology even remotely, since models can be used in the cloud with maximum security.

Interest in in silico technologies is growing exponentially. The global bio-simulation market was estimated to be around $ 1.65 billion in 2018 and is expected to hit 4.58 billion by 2025, with a CAGR of 15.7% between 2019 and 2025.

The Drug Safety Suite, a new series of models that help reduce the risk of cardiotoxicity from drugs, is added today to the products offered by InSilicoTrials to pharmaceutical companies. What is it about? Each new molecule can be dangerous for the heart, causing even irreversible arrhythmias: by combining in vitro tests with simulation tests (in silico) it is possible to identify the danger of a molecule in the very early stages of study and therefore eliminate it immediately, reducing the time and costs of experimentation, and even tests on animals.

The Drug Safety Suite also helps identify the correct dosage of the new pharmacological compounds through the virtual screening of different concentrations, orienting in vitro and in vivo tests with consequent drastic reduction of investments and risks of experimentation on animals and humans.

“InSilicoTrials was born with the aim of accelerating innovation in the medical sector, making it cheaper and more accessible,” says Luca Emili, Founder and CEO of InSilicoTrials. “Simulation is one of the most innovative and effective solutions that allow to accelerate the development and subsequent registration of new drugs by increasing the required safety standards. Our simple and intuitive platform is now enriched with the Drug Safety Suite, which we believe will bring a huge advantage to all those companies that need to minimize risks when selecting new molecules for pharmacological use”.

Tags : #InSilicoTrials #GlobalPharmaceuticalIndustry #COVID-19Epidemic #LatestPharmaNews17thNov #DrugSafetySuite #USFDA #EMA #Italy

About the Author


Team Medicircle

Related Stories

Loading Please wait...
-Advertisements-


Trending Now

Dr. Rohan Palshetkar shares his invaluable insights about the Maternal Mortality Rate causes and improvements in India April 29, 2021
It is important to adopt a non-judgmental attitude towards any teenage girl seeking contraceptive advise suggests Dr. Teena Trivedi, Obstetrician and GynecologistApril 16, 2021
80% of the diseases are psychosomatic which means they have roots in the mind and this is where homeopathy steps in - It resolves physical ailments by finding the cause in the mind – Dr. Sanket Dhuri, Consultant Homeopath April 14, 2021
A futuristic Vision of a Healthcare Entrepreneur: Shyatto Raha, CEO, and Founder of MyHealthcareApril 12, 2021
Saher Mehdi, Founder and Chief Scientist at wellOwise talks about aspects making healthcare more equitable and reachableApril 10, 2021
Wide variety of therapies to address autism in children explained by Dr. Shilpa Jasubhai, Clinical PsychologistApril 09, 2021
Allopathic and Homeopathic medicines should not be taken together says Dr. Sunil Mehra, Homeopath ConsultantApril 08, 2021
The charm of homeopathic medicine is that it can be taken with conventional medicines – Dr. Shruthi Shridhar, Consulting Homeopath April 08, 2021
Dissociative Identity Disorder and associated concepts explained by Dr. Vinod Kumar, Psychiatrist and Head of Mpower - The Centre (Bangalore) April 07, 2021
Dissociative Identity Disorder explained by Dr. Shilpa Jasubhai, Clinical PsychologistApril 05, 2021
Sehat Ki Baat, Karishma Ke Saath- Episode 6 Healthy Diet For Boosting Metabolism Which Can Help Thyroid Patients April 03, 2021
Significant Pointers on Kidney Health by Dr. Santosh Waigankar, Consultant Urooncologist and Robotic Surgeon at Kokilaben Dhirubhai Ambani HospitalApril 01, 2021
Dr. Vaishal Kenia, Ophthalmologist Talks About the Different Possibilities Available for the Treatment of Glaucoma Depending Upon Their Type and SeverityMarch 30, 2021
No Definitive Role of Diet in Treatment of Lymphedema but Intake of Calories, Salt and Long Chain Fatty Acids should be controlled says Dr. Ramani CVMarch 30, 2021
Dr. Kiran Chandra Patro, Senior Nephrologist Talks About Dialysis as the Temporary Process and Not a Permanent Cure for the Patients of Renal DysfunctionMarch 30, 2021
Two out of three new chronic kidney disease patients are found to have diabetes or hypertension informs Dr. Sreeharsha HarinathaMarch 30, 2021
Glaucoma Treatment: Medications or Surgery? A valuable piece of advice from Dr. Pranay Kapdia, Chairman and Medical Director of Kapadia Eye CareMarch 25, 2021
Dr. Shraddha Satav, Consultant Ophthalmologist Recommends that Everybody After 40, Should Go for the Complete Eye Checkup at Regular IntervalMarch 25, 2021
Childhood Obesity is not a Disease but a Condition which can be very well ManagedMarch 19, 2021
World Sleep Day - 19 th March 2021- Know More About Healthy Sleep As Per The Guidelines by The World Sleep Society March 19, 2021